News

Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade)
B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...